Abstract
IntroductionReal world experience with Reveal LinQ, a novel implantable loop recorder for management of cardiac arrhythmias is lacking.MethodsWe aimed to report a large, single center clinical experience with LinQ device. We performed a retrospectively study including all consecutive patients who underwent a LinQ monitor implantation at our center between January 2014 to June 2015.ResultsA total of 233 patients were included in the study. Mean age of the population was 60 ±16.5 years with 102 (44%). The indications for implantation were syncope (37.3%), palpitations (24%), AF management (18%), near syncope (5.2%), cryptogenic stroke (3.9%), bradycardia (3.9%), NSVT (1.7%) and long QT (1.3%). A total of 89 (39%) had a diagnosis made during the follow-up time 8 ±4 months. Of these 57 (25%) and 32 (14%) had a diagnosis made in <90 and >90 days after implantation respectively. Diagnoses made were AF 22(24.7%), SVT 17(19%), Sick sinus syndrome 10(11%), symptomatic bradycardia 2 (2%), advanced heart block 4 (4.4%), PVC 4 (4.4%), VT 1(1%), other 29 (32.5%). These diagnoses led to change in medication 19 (21%), office visits 17 (19%), radiofrequency ablation 23 (26%), pacemaker implantation 18 (20%), ICD implantation 4 (4%), and miscellaneous 9 (10%). 24 patients underwent device explantation. A total of 3440 CareLink transmissions occurred during the follow up (mean of 15 transmissions per patient).ConclusionsIn this largest reported experience with LinQ device, we found LinQ to be an extremely useful tool to diagnose arrhythmia with about 40% patients being diagnosed within 8 months follow-up time.